Understanding how epigenetic changes can increase lung cancer risk
Official title: Defining signatures of epigenetic sensitization to lung cancer in a mouse model
Funded at Yale University · NIH-10862318 · Data updated 2026-11-12
This study is looking at how changes in the way genes are turned on or off in lung tissue might help us spot the risk of lung cancer early on, using mice to find clues that could lead to better ways to diagnose and treat lung cancer for patients like you.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | July 9, 2024 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $234,730 |
| NIH project number | 1R21CA288677-01 |
| Project ID | NIH-10862318 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with a family history of lung cancer or those who have been identified as at high risk due to genetic factors.
✕Less likely to help
Patients with lung cancer who do not have identifiable epigenetic changes or genetic mutations may not benefit from this research.
What this research studies
This research investigates how specific epigenetic changes in lung tissue can influence the development of lung cancer. Using a mouse model, the study aims to identify early epigenetic signatures that may predict cancer risk before tumors actually form. By examining the effects of genetic mutations and epigenetic alterations, the research seeks to improve risk stratification and treatment targeting for lung cancer patients. The findings could lead to better diagnostic tools and therapeutic strategies based on individual epigenetic profiles.
Why it matters
Potential benefit: If successful, this research could lead to more accurate predictions of lung cancer risk and personalized treatment options for patients.
How similar studies have gone: Previous research has shown promising results in understanding the role of epigenetics in cancer, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Yale University
New Haven, United States Active
Researchers
- Principal investigator: Lesch, Bluma J — Yale University
- Study coordinator: Lesch, Bluma J
Related research
Other NIH-funded projects on the same topics.
-
Blood-based markers to identify lung cancer risk in never-smokers
A researchers team at NYU School of Medicine is testing blood tests that might flag higher lung cancer risk in people who have never smoked, helping decide who might need screening.
-
Integrative Analysis of Lung Cancer Risk and Its Causes
A large, multi-part study at the University of New Mexico is exploring why lung cancer happens and how to better prevent and detect it.
-
Integrative Analysis of Lung Cancer Risk and Causes
A large NIH project is exploring how tobacco use, behavior, biology, and screening practices influence lung cancer risk and outcomes to help prevent and detect it earlier.
-
Digital health strategies to expand lung cancer screening in safety-net clinics
A funded project aims to help low-resource clinics increase the use of lung cancer screening for patients who smoke or are at risk.
-
Proteomics-guided matching of lung cancer tumors to preclinical models
This grant aims to improve how we match a patient’s lung cancer tumor to the right preclinical models using protein data.
-
Optimizing lung cancer care with smart tools for prevention, early detection, treatment, and survivorship
A U01 grant using AI and biomarkers to improve lung cancer prevention, screening, treatment, and survivorship care for people at risk or living with lung cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.